[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,436,213
  • Shares Outstanding, K 1,047,354
  • Annual Sales, $ 113,290 K
  • Annual Income, $ -351,400 K
  • EBIT $ -261 M
  • EBITDA $ -246 M
  • 60-Month Beta 0.03
  • Price/Sales 66.56
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 95.23% (-1.57%)
  • Historical Volatility 68.88%
  • IV Percentile 20%
  • IV Rank 25.52%
  • IV High 182.84% on 01/20/26
  • IV Low 65.20% on 12/30/25
  • Expected Move (DTE 5) 0.52 (7.30%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 11,420
  • Volume Avg (30-Day) 26,988
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 625,914
  • Open Int (30-Day) 621,974
  • Expected Range 6.58 to 7.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.09
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.79 +4.50%
on 06/05/26
8.64 -17.82%
on 05/20/26
-1.02 (-12.56%)
since 05/12/26
3-Month
6.54 +8.56%
on 03/24/26
9.54 -25.58%
on 03/23/26
-0.72 (-9.21%)
since 03/12/26
52-Week
1.95 +264.10%
on 12/31/25
12.43 -42.88%
on 02/25/26
+3.91 (+122.57%)
since 06/12/25

Most Recent Stories

More News
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC)

IBRX : 7.10 (-1.39%)
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class...

IBRX : 7.10 (-1.39%)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

NEW YORK , May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).

IBRX : 7.10 (-1.39%)
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their...

IBRX : 7.10 (-1.39%)
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman

SAN FRANCISCO , May 26, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio...

IBRX : 7.10 (-1.39%)
IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

NEW YORK , May 23, 2026 /PRNewswire/ --

IBRX : 7.10 (-1.39%)
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

IBRX Investors with Losses Encouraged to Contact the Firm Before May 26th Deadline

IBRX : 7.10 (-1.39%)
ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 ...

IBRX : 7.10 (-1.39%)
Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy IBRX securities between January 19, 2026, and March 24, 202 6?

IBRX : 7.10 (-1.39%)
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , May 22, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

IBRX : 7.10 (-1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 7.54
2nd Resistance Point 7.43
1st Resistance Point 7.27
Last Price 7.10
1st Support Level 6.99
2nd Support Level 6.87
3rd Support Level 6.71

See More

52-Week High 12.43
Fibonacci 61.8% 8.43
Fibonacci 50% 7.19
Last Price 7.10
Fibonacci 38.2% 5.95
52-Week Low 1.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.